ArticleInfectious agents and cancer2025
HPV prevalence and genotype distribution among women in sanming, China: a retrospective analysis before large-scale vaccination.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo study the prevalence of HPV in Sanming, China before conducting large-scale HPV vaccination is important to guide public health preventive measures and maximize the effectiveness of vaccination.
objectiveProvide an overall understanding of the prevalence of HPV in Sanming to help guide HPV screening and vaccine selection in the future.
methodsA retrospective analysis of 11,886 female patients who underwent cervical screening was performed. We analyzed the overall HPV prevalence in the region, the prevalence based on each age group and different genotypes and the distribution of HPV with different pathological diagnoses.
resultsThe overall HPV prevalence was 17.85%, with peak positivity in the ≤ 20-year group (42.24%) and secondary elevation in 61-70-year-olds (31.90%). HPV52 (23.37%), HPV58 (14.00%), and HPV16 (11.40%) constituted the dominant genotypes. Among 2,122 HPV-positive patients, pathological diagnoses included: chronic cervicitis (83.22%, 1,766/2,122; predominantly HPV52 [22.88%]), low-grade squamous intraepithelial lesions (LSIL, 11.50%, 244/2,122; HPV52 [29.92%]), high-grade SIL (HSIL, 3.49%, 74/2,122; HPV16 [40.54%]), and cervical cancer (1.79%, 38/2,122; HPV16 [52.63%]). Notably, HPV16 prevalence increased significantly with lesion severity.
conclusionThis study found that the overall HPV infection rate in Sanming, China, was slightly higher than in other regions of the country, and the main prevalent genotypes were HPV52 and HPV58. In order to maximize patient benefit, vaccine selection should ideally cover other common genotypes in the region, in addition to HPV16 and HPV18.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.